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The circumsporozoite protein (CSP) builds up the surface coat of sporozoites and is the 22 
leading malaria pre-erythrocytic-stage vaccine candidate. CSP has been shown to induce 23 
robust CD8+ T cell responses that are capable of eliminating developing parasites in 24 
hepatocytes resulting in protective immunity. In this study, we characterised the importance 25 
of the immunodominant CSP-derived epitope, SYIPSAEKI, of Plasmodium berghei in both 26 
sporozoite- and vaccine-induced protection in murine infection models. In BALB/c mice, 27 
where SYIPSAEKI is efficiently presented in the context of the major histocompatibility 28 
complex class I (MHC-I) molecule H-2-Kd, we established that epitope-specific CD8+ T cell 29 
responses contribute to parasite killing following sporozoite immunisation. Yet, sterile 30 
protection was achieved in the absence of this epitope substantiating the concept that other 31 
antigens can be sufficient for parasite-induced protective immunity. Furthermore, we 32 
demonstrated that SYIPSAEKI-specific CD8+ T cell responses elicited by viral-vectored 33 
CSP-expressing vaccines effectively targeted parasites in hepatocytes. The resulting sterile 34 
protection strictly relied on the expression of SYIPSAEKI. In C57BL/6 mice, which are unable 35 
to present the immunodominant epitope, CSP-based vaccines did not confer complete 36 
protection, despite the induction of high levels of CSP-specific antibodies. These findings 37 
underscore the significance of CSP in protection against malaria pre-erythrocytic stages and 38 
demonstrate that a significant proportion of the protection against the parasite is mediated by 39 
CD8+ T cells specific for the immunodominant CSP-derived epitope. 40 
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Malaria is caused by a protozoan parasite of the genus Plasmodium and remains a major 43 
global health challenge in tropical and subtropical countries (1). A vaccine that diminishes the 44 
burden of disease and prevents malaria transmission remains a decisive goal for malaria 45 
elimination programmes. As a gold standard in malaria vaccination, multiple immunisations 46 
of J-radiation-attenuated Plasmodium sporozoites (RAS) can completely protect against wild-47 
type (WT) sporozoite challenge (2-4). This parasite-induced protection targets the developing 48 
exo-erythrocytic forms in hepatocytes, also called liver stages, and completely abrogates 49 
blood stage infection. Antibodies and T cells have been implicated as important mechanisms 50 
of parasite-induced protection (reviewed in (5)), and CD8+ T cells are the prime mediators of 51 
cell-mediated protective immunity, as exemplified in murine (6, 7) and non-human primate (8) 52 
infection models. 53 
 54 
The circumsporozoite protein (CSP), the major surface coat protein of the malaria sporozoite, 55 
has been at the forefront of vaccination studies – being the basis of RTS,S/AS01, the most 56 
progressed malaria vaccine candidate to date (9). Immunisation of BALB/c mice 57 
with Plasmodium berghei (Pb) or P. yoelii (Py) RAS evokes immunodominant major 58 
histocompatibility complex class I (MHC-I) H-2-Kd-restricted CD8+ T cell responses (10, 11) 59 
against distinct CSP epitopes: SYIPSAEKI for Pb (12) and SYVPSAEQI for Py (13). Indeed, 60 
the measurement of responses to these epitopes has become the standard in fundamental 61 
immunological studies in BALB/c mice and their role in parasite-induced protection from 62 
sporozoite challenge has been repeatedly demonstrated (6, 12, 14). Furthermore, numerous 63 
vaccination studies involving different viral-vectored CSP- or CSP epitope-expressing 64 
vaccines – used alone or in combination as part of prime-boost regimens – have 65 
corroborated that CSP is a highly protective antigen in the BALB/c infection model (15-21). In 66 
these studies, elevated levels of either SYIPSAEKI- or SYVPSAEQI-specific CD8+ T cell 67 
responses correlated with protection.  68 
 69 

















Nonetheless, several studies have interrogated and contested the immunological relevance 70 
of CSP with regard to parasite-induced protection in contrast to vaccine-induced protection. 71 
These studies emanated from observations that in naturally exposed humans T cell 72 
responses to CSP are scarce (22). In murine malaria models, multiple immunisations are 73 
required to elicit CD8+ T cell-dependent protective immunity in various mouse strains, 74 
particularly where no other strongly immunogenic CSP-derived CD8+ T cell epitopes have 75 
been identified (23). Furthermore, in PyCSP-transgenic BALB/c mice that are tolerant to 76 
PyCSP, complete protection can be achieved by Py RAS immunisation (24). In good 77 
agreement, BALB/c mice immunised with Pb WT parasites are completely protected when 78 
challenged with transgenic Pb parasites where the endogenous CSP has been swapped with 79 
the P. falciparum CSP (25). Taken together, these studies indicate that immune responses to 80 
CSP are dispensable for protection, and that other antigens are important to elicit protective 81 
immunity.  82 
 83 
In this study, we have extended previous work on the entire CSP by dissecting the relevance 84 
of a single CSP-derived immunodominant epitope in parasite- and vaccine-induced 85 
protection. As the most stringent model system, we utilised transgenic Pb parasites lacking 86 
SYIPSAEKI for immunisation and challenge experiments in BALB/c mice. In addition, we 87 
have highlighted the level of protection achieved by CSP-based vaccines in mice expressing 88 
the relevant (BALB/c) or irrelevant (C57BL/6) MHC-I needed to present the CSP-derived 89 
immunodominant epitope. 90 
  91 


















Sporozoite-induced SYIPSAEKI-specific CD8+ T cell responses contribute to parasite 93 
killing but are dispensable for the development of sterile immunity.  94 
First, we interrogated the role that SYIPSAEKI, the H-2-Kd-restricted immunodominant 95 
epitope of PbCSP, plays in protective immunity induced after live attenuated sporozoite 96 
immunisation. For this purpose, PbCSPSIINFEKL radiation-attenuated sporozoites (RAS), where 97 
the SYPSAEKI sequence has been replaced with the H-2-Kb-restricted epitope of ovalbumin, 98 
SIINFEKL ((26), Müller and Gibbins et al., unpublished) were used to immunise H-2-Kd-99 
expressing BALB/c mice. To date, there are no other reported strongly immunogenic H-2-Kd-100 
restricted PbCSP epitopes identified. Removal of SYPSAEKI, by replacement with an 101 
irrelevant epitope, in the PbCSPSIINFEKL parasites allows unequivocal assignment of critical 102 
roles of this immunodominant PbCSP-derived epitope in protection elicited by live sporozoite 103 
immunisations. Two weeks after immunisation, the frequencies of IFN-J-producing 104 
SYIPSAEKI-specific CD8+ T cell responses in the spleen after gating for CD11a expression 105 
(an activation marker commonly used to identify antigen-experienced cells (27)) were 106 
measured by flow cytometry (Fig. 1A). As expected, PbCSPSIINFEKL RAS parasites elicited no 107 
SYIPSAEKI-specific CD8+ T cell responses in BALB/c mice.  108 
 109 
To ascertain whether SYIPSAEKI contributes to parasite-induced protection, BALB/c mice 110 
were immunised once (Fig 1B) or twice (Fig 1C) with either PbWT or PbCSPSIINFEKL RAS. 111 
Two weeks after immunisation, the mice were challenged with PbWT sporozoites and 112 
protection was determined by measuring the parasite loads in the liver 40 hours later (Fig. 1B 113 
and C). A significant reduction in parasite load – up to four orders of magnitude difference as 114 
compared to naïve mice – was observed in mice immunised with PbWT RAS and challenged 115 
with PbWT parasites. In contrast, protection was reduced only by approximately two orders 116 
of magnitude (after one immunisation) or three orders of magnitude (after two immunisations) 117 
in mice immunised with PbCSPSIINFEKL RAS (Fig. 1B and C). These results highlight the 118 
notion that within PbCSP, the SYIPSAEKI epitope has a critical and immunodominant 119 
contribution to protecting BALB/c mice after one or two immunisations with RAS. 120 


















However, multiple immunisations with RAS are required to induce sterile protection. To 122 
establish whether the development of sterile immunity is dependent on SYIPSAEKI-specific 123 
CD8+ T cell responses, BALB/c mice were immunised thrice with PbCSPSIINFEKL RAS one 124 
week apart; two weeks after the last immunisation, mice were challenged with PbWT 125 
sporozoites (Fig. 1C). All mice were protected from blood stage infection compared to the 126 
naïve controls, implying that SYIPSAEKI-specific CD8+ T cell responses are not necessary 127 
for the development of sterile immunity. 128 
 129 
Prime-boost vaccination with CSP-expressing viruses induces strong anti-CSP 130 
antibody and CD8+ T cell responses and SYIPSAEKI is the key mediator of sterile 131 
protection.  132 
Next, we probed the requirement for SYIPSAEKI presentation in protection elicited by viral-133 
vectored CSP-expressing vaccines administered in a prime-boost regimen. Priming with 134 
adenovirus (Ad) carrying a foreign antigen and boosting with orthopoxvirus modified vaccinia 135 
Ankara (MVA) expressing the same antigen has consistently been shown to induce strong 136 
CD8+ T cell responses with high levels of protective efficacy against intracellular pathogens 137 
including malaria pre-erythrocytic stages (18, 21). 138 
 139 
Chimpanzee adenovirus serotype 63 (AdCh63) and MVA vaccines expressing PbCSP were 140 
used to vaccinate BALB/c mice with a two-week resting period between priming and boosting 141 
(Fig. 2A). Two weeks after boosting, whole blood was collected and restimulated ex vivo with 142 
SYIPSAEKI peptide. The frequencies of IFN-J secreting CD8+ T cells were enumerated by 143 
flow cytometry (Fig. 2B) and Ad-MVA PbCSP-vaccinated mice elicited ~12% SYIPSAEKI-144 
specific circulating CD8+ T cells (Fig. 2C), which is consistent with the level of epitope-145 
specific CD8+ T cells induced by similar, previously published, viral vectored prime-boost 146 
regimens (19, 21). Serum samples were also collected from the vaccinated animals and 147 
were used in an immunofluorescence assay against air-dried Pb sporozoites (Fig. 2D). Ad-148 
MVA PbCSP-vaccinated BALB/c mice induced high anti-CSP antibody tires (1:104). These 149 

















data indicate that Ad-MVA PbCSP vaccination elicit both high frequencies of SYPSAEKI-150 
specific CD8+ T cells and high titres of CSP-specific antibodies.   151 
 152 
Two weeks after boosting, Ad-MVA PbCSP-vaccinated mice were challenged with PbWT or 153 
PbCSPSIINFEKL parasites. Protection was assessed by two complementary assays; (i) 154 
determination of the reduction of parasite load in the liver (Fig. 2E) and (ii) induction of sterile 155 
protection (Fig. 2F). Strikingly, parasite load in the liver of Ad-MVA PbCSP-vaccinated mice 156 
was not significantly reduced compared to non-vaccinated mice when challenged with 157 
PbCSPSIINFEKL sporozoites, in marked contrast to challenge with PbWT sporozoites. In perfect 158 
agreement, vaccinated mice challenged with PbCSPSIINFEKL sporozoites were patent for 159 
parasitaemia by day 5, whereas vaccinated mice challenged with PbWT sporozoites 160 
remained completely protected. These results denote that vaccine-induced effector 161 
SYIPSEAKI-specific CD8+ T responses efficiently target parasites expressing the cognate 162 
epitope. Parasites lacking the SYIPSAEKI epitope are not eliminated despite high levels of 163 
CSP-specific antibodies evoked by vaccination in this experimental system. 164 
 165 
CSP-based vaccines do not elicit protective immunity in C57BL/6 mice.  166 
To further investigate the requirement of SYIPSAEKI as the indispensable protective epitope 167 
of CSP, mice unable to present this epitope were vaccinated with the PbCSP prime-boost 168 
regimen with an interval of two weeks between vaccines, followed by challenge with either 169 
PbWT or PbCSPSIINFEKL parasites (Fig 3A). C57BL/6 mice were used because SYIPSAEKI is 170 
an H-2-Kd restricted epitope, and this mouse strain does not express the relevant MHC-I 171 
allele. Thus, SYIPSAEKI would fail to be presented by infected hepatocytes. As before, blood 172 
and serum were derived two weeks after boost. As expected, SYIPSAEKI-specific CD8+ T 173 
cells (Fig. 3B) were not detectable in Ad-MVA PbCSP-vaccinated C57BL/6 mice (Fig. 3C), 174 
but strong anti-CSP antibody titres (1:104) were elicited (Fig. 3D). Ad-MVA CSP-vaccinated 175 
C57BL/6 mice challenged with either PbWT or PbCSPSIINFEKL parasites had comparable 176 
parasite load in the liver (Fig. 3E), indicative of full liver stage development in all groups. 177 
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DISCUSSION  179 
Our findings lend full support to the notion that CSP is an immunodominant sporozoite-180 
derived antigen (24). A single epitope, SYIPSAEKI, is the immunodominant CD8+ T cell 181 
epitope of CSP, and we show that it is responsible for the antigen’s protective capacity 182 
against parasites in the liver in the BALB/c model. Following RAS immunisation, CD8+ T cell 183 
responses to SYIPSAEKI contribute to the reduction in parasite load in the liver following 184 
sporozoite challenge, as shown herein. When RAS-immunised mice are challenged with 185 
PbCSPSIINFEKL, transgenic parasites lacking SYIPSAEKI, reduced anti-Plasmodium activity in 186 
the liver is observed. Nonetheless, complete protection is achievable in the absence of 187 
SYIPSAEKI-specific CD8+ T cell responses, demonstrating that responses to other, yet 188 
unidentified, H-2-Kd-restricted epitopes contribute to parasite killing. It is conceivable that 189 
these epitopes are encoded by the hundreds of other Plasmodium genes expressed in 190 
malaria pre-erythrocytic stages, some of which might be shared with blood stage antigens 191 
(28).  192 
 193 
Our findings also emphasise the importance of SYIPSAEKI-specific CD8+ T cell responses 194 
for promoting protective immunity when using CSP-based viral vaccines in the BALB/c 195 
model. These vaccines are aimed at generating high levels of epitope-specific memory CD8+ 196 
T cells but rely on the expression of relevant MHC-I in the vaccinated host and the presence 197 
of the cognate epitope in the parasite used for challenge (29). Notably, despite high levels of 198 
antibodies against whole sporozoites elicited following Ad-MVA PbCSP vaccination, sterile 199 
protection was not achieved following challenge of C57BL/6 mice. These mice cannot 200 
present SYIPSAEKI, fully supporting the notion that the protective efficacy of CSP strictly 201 
depends on the expression of the immunodominant epitope. These findings were 202 
independently corroborated by the lack of protection in mice, either BALB/c or C57BL/6, 203 
immunised with transgenic sporozoites lacking SYIPSAEKI.  204 
 205 
Together, these results have important implications for the development of next generation 206 
malaria vaccines. We have demonstrated the significance of a single epitope of CSP in 207 

















mediating protective CD8+ T cell responses while also recapitulating that protection can be 208 
achieved in the absence of responses to the entire CSP antigen (24, 25). In BALB/c mice, 209 
SYIPSAEKI-specific CD8+ T cell responses offered protection. However, to achieve 210 
complete sterile protection either multiple sporozoite immunisations or viral vaccines, which 211 
induced large populations of SYIPSAEKI-specific CD8+ T cells, were required. Multiple 212 
immunisations likely induced a broad range of immune responses and multiple high-dose 213 
immunisations with RAS in humans have been shown to induce dose-dependent anti-214 
sporozoite CD8+ T cell responses in addition to dose dependent anti-sporozoite antibody 215 
and CD4+ T cell responses (4). It will be important in the future to determine how the 216 
magnitude of SYIPSAEKI-specific CD8+ T cell responses modulates, after consecutive 217 
immunisations, but also the breadth of responses to other CSP epitopes (B and T cell) and 218 
their effect on protection compared to other antigens. In line with this, our findings also show 219 
that protection can be achieved in the absence of responses to immunodominant epitopes, 220 
leading us to suggest that future pre-erythrocytic malaria vaccine research should not only 221 
focus on inducing strong CD8+ T cell responses against one or multiple antigens but should 222 
try to target a broad array of antigens and cover diverse MHC to offer the best protection 223 
possible. The identification of novel antigens and epitopes that contribute to protection in H-224 
2-Kd-restricted BALB/c mice, and ultimately in human populations with broad MHC 225 
haplotypes, will aid this development. In C57BL/6 mice pre-erythrocytic immunity is mounted 226 
irrespective of CSP-specific CD8+ T cell responses, and recent genome-wide epitope 227 
profiling returned multiple sporozoite antigens and epitopes (30-32). RTS,S/AS01, the 228 
leading subunit malaria vaccine based on CSP, seems to offer some protection against P. 229 
falciparum re-infection (9). Partial and short-lived protection is likely primarily mediated by the 230 
action of transitory anti-sporozoite antibodies (33-35). Strikingly, peripheral blood CD8+ T cell 231 
responses were not identified to provide a role following sporozoite challenge in this 232 
candidate vaccine. Together with previous findings (7, 17, 19, 24) our data underscore efforts 233 
to improve the most advanced candidate malaria vaccine, RTS,S/AS01, by eliciting CD8+ T 234 
cells against CSP or other immunodominant antigens. 235 
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MATERIALS AND METHODS 237 
Ethics and animal experimentation. Animal procedures were performed in accordance 238 
with the German ‘Tierschutzgesetz in der Fassung vom 18. Mai 2006 (BGBl. I S. 1207)’ 239 
which implements the directive 2010/6 3/EU from the European Union. The protocol was 240 
approved by the ethics committee of the Berlin state authority (‘Landesamt für Gesundheit 241 
und Soziales Berlin’, permit number G0469/09). Animal experiments at London School of 242 
Hygiene and Tropical Medicine were conducted under license from the United Kingdom 243 
Home Office under the Animals (Scientific Procedures) Act 1986. CD-1 mice were bred in-244 
house at LSHTM, while NMRI, C57BL/6 and BALB/c laboratory mouse strains were 245 
purchased from either Charles River Laboratories (Margate, UK or Sulzfeld, Germany) or 246 
Janvier (Saint Berthevin, France). Female mice of 6-8 weeks of age were used in the 247 
experiments. 248 
 249 
Plasmodium parasites and immunisation. The transgenic P. berghei ANKA CSPSIINFEKL 250 
(PbCSPSIINFEKL) parasite was generated with the immunodominant CSP CD8+ T cell epitope 251 
SYIPSAEKI (252-260aa) being replaced with the H-2-b restricted Gallus gallus ovalbumin 252 
CD8+ T cell epitope SIINFEKL (258-265aa) via double homologous recombination ((26), 253 
Müller and Gibbins et al., unpublished). Wild-type Plasmodium berghei ANKA (clone 254 
c115cy1) (PbWT) and PbCSPSIINFEKL were maintained by continuous cycling between murine 255 
hosts (NMRI or CD-1) and Anopheles stephensi mosquitos. Infected mosquitos were kept in 256 
incubators (Panasonic and Mytron) at 80% humidity and 20°C temperature. Sporozoites 257 
were isolated from the salivary glands and attenuated by J-irradiation at 1.2x104cGy. Mice 258 
were immunised with 10,000 sporozoites administered intravenously with multiple doses 259 
given one week apart unless otherwise stated. For challenge infections, 5,000 or 10,000 260 
sporozoites were administered intravenously to assess sterile protection and parasite load in 261 
the liver, respectively.  262 
 263 
Viral-vectored CSP-expressing vaccines. AdCh63 and MVA vaccines expressing the 264 
mammalian codon-optimised fragment of PbCSP were constructed and propagated based 265 

















on previously published viral vectors (36, 37). The viral vectors were administered 266 
intramuscularly in endotoxin-free PBS at a concentration of 105 viral particles for AdPbCSP 267 
for the prime immunisation and 106 viral particles MVAPbCSP for the boost immunisation. 268 
 269 
Immunofluorescent antibody assay. 10,000 sporozoites were spotted onto epoxy coated 270 
glass slides with marked rings (Medco), dried at room temperature and stored at -20°C. 271 
Thawed slides were fixed in acetone, dried and rehydrated with PBS before incubation in 272 
10% FCS supplemented DMEM (Gibco) for 1 hour at 37°C in a humid chamber. Serum at 273 
concentrations 1:103, 1:3.3x103, 1:104, 1:3.3x104, 1:105 (and, additionally, 1:3.3x105 and 274 
1:106 for C57BL/6 serum) were added to the ring wells and incubated for 1 hour at 37°C in a 275 
humid chamber. Slides were washed and stained with a mouse anti-CSP (38) primary 276 
antibody. Hoechst33342 was added as the nuclear stain together with a respective 277 
fluorescently labelled anti-mouse secondary antibody for a further one-hour incubation. 278 
Slides were washed and mounted with 'Fluoromount-G' (Southern Biotech) and analysed by 279 
fluorescent microscopy (Zeiss Axio Observer).  280 
 281 
Quantification of SYIPSAEKI-specific CD8+ T cell responses. Spleens were harvested 282 
and lymphocytes were derived by passing spleens through 40Pm cell strainers (Corning). 283 
Peripheral blood was drawn from the tail vein and collected in Na+ heparin capillary tubes 284 
(Brand) and assayed in 96-well flat bottom plates (Corning). Red blood cells were lysed 285 
using PharmLyse (BD) and lymphocytes were resuspended in 10% FCS, 2% Penicillin-286 
Streptomycin and 1% L-glutamine supplemented RPMI 1640 (Gibco). Splenocytes were 287 
counted using a 40x dilution with Trypan Blue (ThermoFisher Scientific) and a Neubauer 288 
‘Improved’ haemocytometer (Biochrom). 2x106 splenocytes and the lysed blood samples 289 
were prepared in 96 well plates and incubated with a final concentration of 10Pg/ml of 290 
SYIPSAEKI peptide in in the presence of Brefeldin A (eBioScience) for 5-6 hours at 37°C 291 
and 5% CO2. For staining of cell surface markers and intracellular cytokines, cells were 292 
incubated for 1 hour at 4°C for each staining. Cells were stained for CD8 (53-6.7) and CD11a 293 

















(M17/4) (eBiosience). Splenic cells were fixed with 4% paraformaldehyde and peripheral 294 
blood cells were fixed with 1% paraformaldehyde before staining for IFN-J (XMG1.2) 295 
(eBioscience) in the presence of Perm/Wash buffer (BD) for intracellular staining. Data was 296 
acquired by flow cytometry using an LSRFortessa or LSRII (BD) and analysed using 297 
Flowjo9.5.2 (Tree Star, Inc.). 298 
 299 
Quantification of parasite load in the liver. Livers were harvested 40-42 hours after 300 
sporozoite challenge and total RNA was extracted following homogenisation using TRIzol 301 
(ThermoFisher Scientific). cDNA was generated using the RETROScript Kit (Ambion). 302 
Quantitative real-time PCR was performed using the StepOnePlus Real-Time PCR System 303 
and Power SYBR Green PCR Master Mix (Applied Biosystems). Relative liver parasite levels 304 
were quantified using the ΔΔCt method comparing levels of P. berghei 18S rRNA using 305 
specific primers and normalised to levels of mouse GAPDH mRNA (39).  306 
 307 
Assessment of parasitaemia. Sterile protection was assessed by daily blood smears, taken 308 
from mice 3-14 days after sporozoite challenge, stained with Giemsa (improved solution; 309 
VWR) to microscopically determine the presence of blood stage parasites. 310 
 311 
Statistical analysis. Statistical analysis was performed using GraphPad Prism v7 312 
(GraphPad Software, Inc.). Statistics were calculated using the Mann-Whitney U test. 313 
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FIGURE LEGENDS 477 
FIG 1 SYIPSAEKI is dispensable for RAS immunisation but predominates protection with 478 
fewer immunisations. (A) BALB/c mice were immunised once with 10,000 PbWT or 479 
PbCSPSIINFEKL RAS. Splenocytes were taken after two weeks and restimulated with 480 
SYIPSAEKI peptide. IFN-J-producing cells co-staining with CD11a were assessed by flow 481 
cytometry. Shown are the time course (top), the gating strategy (centre) and proportion of 482 
IFN-J-producing CD11a of total CD8+ T cells (bottom). (B) Groups of BALB/c mice were 483 
immunised once with 15,000 PbWT or PbCSPSIINFEKL RAS. Immunised mice and BALB/c 484 
naïve controls (n=3-10) were challenged with 10,000 PbWT parasites two weeks after the 485 
last immunisation. Livers were harvested 40 hours post-challenge and the relative liver 486 
parasite loads were quantified using the ΔΔCt method comparing levels of P. berghei 18S 487 
rRNA and levels of mouse GAPDH mRNA. Mean values (±SEM) are shown and statistics 488 
were calculated using the Kruskall-Wallis test (***, p<0.001). (C) Groups of BALB/c mice 489 
were immunised twice with 10,000 PbWT or PbCSPSIINFEKL RAS, 1 week apart. Immunised 490 
mice and BALB/c naïve controls (n=5) were challenged with 10,000 PbWT parasites two 491 
weeks after the last immunisation. Livers were harvested 40 hours post-challenge and the 492 
relative liver parasite loads were quantified using the ΔΔCt method comparing levels of P. 493 
berghei 18S rRNA and levels of mouse GAPDH mRNA. Mean values (±SEM) are shown and 494 
statistics were calculated using the Kruskall-Wallis test (***, p<0.001). (D) BALB/c mice 495 
(n=12) were immunised with three doses of 10,000 PbCSPSIINFEKL RAS at one-week intervals. 496 
Immunised mice and naïve controls (n=11) were challenged with 5,000 PbWT sporozoites 16 497 
days after the last immunisation. Blood smears were taken daily for two weeks after 498 
challenge. Parasitaemia was assessed by microscopic examination of Giemsa-stained 499 
smears. Data shown is a combination of two independent experiments. 500 
FIG 2 Prime-boost vaccination with viral vectored CSP-expressing vaccines induces strong 501 
anti-CSP antibody and CD8+ T cell responses, and SYIPSAEKI-specific CD8+ T cell 502 
responses are essential for protection. (A) BALB/c mice were vaccinated with AdCh63 and 503 
MVA vaccines expressing PbCSP (AdPbCSP and MVAPbCSP) and challenged with 10,000 504 

















PbWT or PbCSPSIINFEKL sporozoites as shown. (B) Flow cytometry gating strategy used to 505 
determine proportions of IFN-J+ CD11a+ CD8+ T cells. (C) Proportion of IFN-J-producing 506 
CD11a of total CD8+ T cells. Blood was drawn from the tail from naïve (n=9) and vaccinated 507 
mice (n=10) two weeks after boost and restimulated with SYIPSAEKI and stained for CD8 508 
and CD11a surface markers, and IFN-J for flow cytometric analysis. (D) Reciprocal antibody 509 
titers of mouse serum reactive to whole sporozoites. Serum from naïve (n=11) and 510 
vaccinated mice (n=12) was isolated two weeks after boost and CSP specific antibody titres 511 
were measured by immunofluorescent antibody assay. (E) Livers from vaccinated mice (+) 512 
challenged with PbWT (n=6) or PbCSPSIINFEKL sporozoites (n=5) and non-vaccinated mice (-) 513 
challenged with PbWT (n=5) or PbCSPSIINFEKL sporozoites (n=5) were harvested 42 hours 514 
post-challenge and relative liver parasite levels were quantified using the ΔΔCt method 515 
comparing levels of P. berghei 18S rRNA and levels of mouse GAPDH mRNA. (F) Groups of 516 
vaccinated and non-vaccinated mice (n=6) were challenged with 5,000 PbWT or 517 
PbCSPSIINFEKL sporozoites. Vaccinated mice challenged with PbWT (triangles) or 518 
PbCSPSIINFEKL (squares) and non-vaccinated mice challenged with PbWT (inverted triangles) 519 
or PbCSPSIINFEKL (diamonds) had daily tail smears taken from day 3-14 post challenge. Slides 520 
were stained with Giemsa and parasitaemia was assessed by microscopy. (C-E) Each data 521 
point represents one mouse with mean values (±SEM) shown and statistics were calculated 522 
using the Mann-Whiney test (*, p<0.05; ***, p<0.001). 523 
FIG 3 Prime-boost vaccination with CSP expressing viruses does not protect C57BL/6 mice, 524 
irrespective of induced antibody titres.  525 
(A) C57BL/6 mice were vaccinated with AdCh63 and MVA vaccines PbCSP and challenged 526 
with 10,000 PbWT or PbCSPSIINFEKL sporozoites as shown. (B) Flow cytometry gating 527 
strategy used to determine proportions of IFN-J+ CD11a+ CD8+ T cells. (C) Proportion of 528 
IFN-J-producing CD11a of total CD8+ T cells. Blood was drawn from the tail from naïve 529 
(n=10) and vaccinated mice (n=10) two weeks after boost was restimulated with SYIPSAEKI 530 
and stained for CD8 and CD11a surface markers, and IFN-J for flow cytometric analysis. (D) 531 
Reciprocal antibody titres of mouse serum reactive to whole sporozoites. Serum from naïve 532 

















(n=6) and vaccinated mice (n=9) was isolated two weeks after boost and CSP specific 533 
antibody titres were measured by immunofluorescent antibody assay. (E) Livers from groups 534 
of 5 mice per condition were harvested 42 hours post-challenge and relative liver parasite 535 
levels were quantified using the ΔΔCt method comparing levels of P. berghei 18S rRNA and 536 
levels of mouse GAPDH mRNA. None of the differences were significant (p>0.05). (C-E). 537 
Each data point represents one mouse with mean values (± SEM) shown and statistics were 538 
calculated using the Mann-Whiney test (***p<0.001). 539 
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